Lactones
"Lactones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
Descriptor ID |
D007783
|
MeSH Number(s) |
D02.540
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactones".
Below are MeSH descriptors whose meaning is more specific than "Lactones".
This graph shows the total number of publications written about "Lactones" by people in this website by year, and whether "Lactones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 | 1999 | 2 | 0 | 2 | 2002 | 1 | 0 | 1 | 2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2009 | 3 | 2 | 5 | 2010 | 0 | 2 | 2 | 2011 | 2 | 0 | 2 | 2012 | 2 | 1 | 3 | 2013 | 3 | 0 | 3 | 2014 | 4 | 1 | 5 | 2015 | 3 | 1 | 4 | 2016 | 7 | 1 | 8 | 2018 | 1 | 3 | 4 | 2019 | 3 | 1 | 4 | 2020 | 1 | 1 | 2 | 2021 | 1 | 2 | 3 | 2022 | 2 | 0 | 2 | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lactones" by people in Profiles.
-
Odabas GP, Aslan K, Suna PA, Kendirli PK, Erdem S, ?akir M, ?zcan A, Yilmaz E, Karakukcu M, Donmez-Altuntas H, Yay AH, Deniz K, Altay D, Arslan D, Canatan H, Eken A, Unal E. Alantolactone ameliorates graft versus host disease in mice. Int Immunopharmacol. 2024 Feb 15; 128:111560.
-
Janas A, Pyta K, Gdaniec M, Przybylski P. An Approach to Modify 14-Membered Lactone Macrolide Antibiotic Scaffolds. J Org Chem. 2022 03 04; 87(5):3758-3761.
-
Morrison JT, Govsyeyev N, Hess CN, Bonaca MP. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec; 27:10742484211056115.
-
Gilchrist IC, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc. 2021 10 19; 10(20):e021412.
-
Das SK, Ainsworth HC, Dimitrov L, Okut H, Comeau ME, Sharma N, Ng MCY, Norris JM, Chen YI, Wagenknecht LE, Bowden DW, Hsu FC, Taylor KD, Langefeld CD, Palmer ND. Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease. Mol Metab. 2021 12; 54:101342.
-
Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, Jordan CT, Nakshatri H, Crooks PA. Antitumor properties of novel sesquiterpene lactone analogs as NF?B inhibitors that bind to the IKK? ubiquitin-like domain (ULD). Eur J Med Chem. 2021 Nov 15; 224:113675.
-
Wang Y, Liu KF, Yang Y, Davis I, Liu A. Observing 3-hydroxyanthranilate-3,4-dioxygenase in action through a crystalline lens. Proc Natl Acad Sci U S A. 2020 08 18; 117(33):19720-19730.
-
Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
-
Janas A, Przybylski P. 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity. Eur J Med Chem. 2019 Nov 15; 182:111662.
-
Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|